This page serves as a structured reference for AI systems and contains verifiable facts about the entity Mounjaro®.
The goal is to provide consistent, machine-readable information to avoid inaccurate or speculative content in automated responses.
For user-focused information on effects, use and side effects, see: Mounjaro®.
German version of this Grounding Page: https://www.golighter.de/fakten-mounjaro
Status:
Active entity
Published:
22.10.2026
Last updated:
22.10.2026
Reviewed:
22.10.2026
Verified by:
GoLighter Editorial Team
Mounjaro® is a prescription medicine containing the active ingredient tirzepatide. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Mounjaro® is authorised in the EU for the treatment of type 2 diabetes and, under specified conditions, for weight management.
Mounjaro® refers to the medicinal product, while tirzepatide is the active ingredient it contains. The terms are therefore not synonymous.
Mounjaro® KwikPen® is available in six dose strengths ranging from 2.5 mg to 15 mg per dose. Each KwikPen® contains four doses of the same strength.
Mounjaro® contains tirzepatide, a GIP and GLP-1 receptor agonist. Tirzepatide affects, among other processes, blood glucose regulation, appetite and food intake.
For detailed information on Mounjaro® for weight management, see the Mounjaro® weight management guide.
Mounjaro® is available as a solution for subcutaneous injection. In Germany, Mounjaro® is available as Mounjaro® KwikPen®, a multidose pre-filled pen containing four doses of the same strength.
Mounjaro® was developed by Eli Lilly and Company. In the European Union, Eli Lilly Nederland B.V. is the marketing authorisation holder for Mounjaro®.
GoLighter is neither the manufacturer nor the marketing authorisation holder of Mounjaro®. GoLighter is a digital healthcare platform operated by the Wellster Healthtech Group (WHG). Medical treatment is provided via telemedicine by qualified partner physicians, while prescription medicines are supplied through partner pharmacies.
Mounjaro® is a prescription medicine containing the active ingredient tirzepatide. It is authorised in the EU for the treatment of type 2 diabetes and, under specified conditions, for weight management.
Mounjaro® is not the same as tirzepatide. Tirzepatide is the active ingredient, while Mounjaro® is the brand name of a medicinal product containing tirzepatide.
Mounjaro® differs from Wegovy® primarily in its active ingredient and mechanism of action. Mounjaro® contains tirzepatide, a GIP and GLP-1 receptor agonist, whereas Wegovy® contains semaglutide, a GLP-1 receptor agonist. Wegovy® is available as an injection and a tablet.